Immuneering (IMRX) Cash & Equivalents (2020 - 2026)
Immuneering (IMRX) posted quarterly Cash & Equivalents of $47.3 million for Q1 2026, up 31.94% year-over-year from $35.9 million in Q1 2025, and down 63.22% quarter-over-quarter from $128.6 million in Q4 2025.
Immuneering (IMRX) Cash & Equivalents (2020 - 2026) Analysis & Trends
Immuneering's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $47.3 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 31.94% year-over-year to $47.3 million; the TTM figure through Mar 2026 stood at $47.3 million (up 31.94% YoY), while the FY2025 annual figure was $128.6 million, up 255.92% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $47.3 million, down from $128.6 million in the prior quarter.
- The five-year high for Cash & Equivalents was $227.6 million in Q3 2025, with the low at $26.4 million in Q2 2025.
- The 5-year median for Cash & Equivalents is $68.0 million (2023), against an average of $76.1 million.
- Peak annual rise in Cash & Equivalents reached 403.4% in 2025, while the deepest fall reached 55.87% in 2025.
- Immuneering's Cash & Equivalents stood at $72.6 million in 2022, then slipped by 18.22% to $59.4 million in 2023, then sank by 39.16% to $36.1 million in 2024, then surged by 255.92% to $128.6 million in 2025, then tumbled by 63.22% to $47.3 million in 2026.
- Business Quant data shows IMRX's Cash & Equivalents at $47.3 million in Q1 2026, $128.6 million in Q4 2025, and $227.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 41.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.32 Mn |
| Mar 31, 2026 | 47.32 Mn |
| Dec 31, 2025 | 128.65 Mn |
| Sep 30, 2025 | 227.56 Mn |
| Jun 30, 2025 | 26.36 Mn |
| Mar 31, 2025 | 35.87 Mn |
| Dec 31, 2024 | 36.14 Mn |
| Sep 30, 2024 | 45.21 Mn |
| Jun 30, 2024 | 59.73 Mn |
| Mar 31, 2024 | 66.29 Mn |
| Dec 31, 2023 | 59.41 Mn |
| Sep 30, 2023 | 68.04 Mn |
| Jun 30, 2023 | 104.02 Mn |
| Mar 31, 2023 | 77.43 Mn |
| Dec 31, 2022 | 72.64 Mn |
| Sep 30, 2022 | 76.42 Mn |
| Jun 30, 2022 | 87.94 Mn |
| Mar 31, 2022 | 75.21 Mn |
| Dec 31, 2021 | 74.89 Mn |
| Sep 30, 2021 | 106.93 Mn |